About the Authors

Federico C. F. Calboli

f.calboli@imperial.ac.uk

Affiliation Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom

Federica Tozzi

Affiliation Genetics Division, Drug Discovery, GlaxoSmithKline R&D, Verona, Italy

Nicholas W. Galwey

Affiliation Discovery Biometrics Respiratory, GlaxoSmithKline, Greenford, United Kingdom

Athos Antoniades

Affiliation Department of Computer Science, University of Cyprus, Nicosia, Cyprus

Vincent Mooser

Affiliation Genetics Division, Drug Discovery, GlaxoSmithKline R&D, Upper Merion, Pennsylvania, United States of America

Martin Preisig

Affiliation Department of Psychiatry, University Hospital Center and University of Lausanne, Lausanne, Switzerland

Peter Vollenweider

Affiliation Department of Internal Medicine, University Hospital Center and University of Lausanne, Lausanne, Switzerland

Dawn Waterworth

Affiliation Genetics Division, Drug Discovery, GlaxoSmithKline R&D, Upper Merion, Pennsylvania, United States of America

Gerard Waeber

Affiliation Department of Internal Medicine, University Hospital Center and University of Lausanne, Lausanne, Switzerland

Michael R. Johnson

Contributed equally to this work with: Michael R. Johnson, Pierandrea Muglia, David J. Balding

Affiliation Department of Clinical Neurosciences, Imperial College London, London, United Kingdom

Pierandrea Muglia

Contributed equally to this work with: Michael R. Johnson, Pierandrea Muglia, David J. Balding

Affiliation Discovery Medicine, Neurosciences CEDD, GlaxoSmithKline R&D, Verona, Italy

David J. Balding

Contributed equally to this work with: Michael R. Johnson, Pierandrea Muglia, David J. Balding

Affiliations Department of Epidemiology and Biostatistics, Imperial College London, London, United Kingdom, Genetics Institute, University College London, London, United Kingdom

Competing Interests

F. Tozzi, V. Mooser, D. Waterworth and N. W. Galwey are GlaxoSmithKline (GSK) full-time employees. P. Muglia was a GlaxoSmithKline full-time employee at the time when this study was performed. M. Johnson was a GSK consultant at the time when the project was initiated. F. Calboli was supported by a GSK grant to Imperial College London. The PsyCoLaus study was supported by grants from the Swiss National Science Foundation (#3200B0-105993, #3200B0-118308, 33CSCO-122661) and from GlaxoSmithKline (Psychiatry Center of Excellence for Drug Discovery and Genetics Division, Drug Discovery - Verona, R&D). GSK's role does not alter the authors' adherence to the PLoS ONE policies on sharing data.

Author Contributions

Conceived and designed the experiments: FCFC FT NWG MJ PM DB. Wrote the paper: FCFC FT NWG MJ DB. Contributed to data analysis and manuscript writing: AA. Contributed to the design of the population based study and to the writing of the manuscript: VM. Conceived the design of the population based study: MP PV GW. Principal Investigators of the study: MP PV GW. Contributed to the design of the current study and critically reviewed the manuscript: MP PV GW. Contributed to the design of the population based study and critically reviewed the manuscript: DW. Supervised the work and contributed with a critical review of the manuscript: PM DB.